Related Experiment Video
Updated: Dec 10, 2025

Visualizing Lung Cellular Adaptations during Combined Ozone and LPS Induced Murine Acute Lung Injury
Published on: March 21, 2021
Alpha-1-antitrypsin: A possible host protective factor against Covid-19
Mariana Braccialli de Loyola1, Thaís Tereza Aguiar Dos Reis1, Guilherme Xavier Lyra Malcher de Oliveira1
1Laboratory of Molecular Neurovirology, Faculty of Health Science, University of Brasília, Brasilia, Brazil.
Alpha-1-antitrypsin (A1AT) inhibits SARS-CoV-2 infection by blocking key proteases like TMPRSS2 and ADAM17. This review explores A1AT
Area of Science:
- Immunology
- Virology
- Biochemistry
Background:
- Understanding COVID-19 pathophysiology is critical for developing effective treatments.
- Alpha-1-antitrypsin (A1AT) possesses known antiviral and anti-inflammatory properties.
- A1AT is a natural tissue protector with potential roles in disease modulation.
Purpose of the Study:
- To review the interplay between A1AT, key proteases (TMPRSS2, ADAM17), and immune molecules in COVID-19.
- To elucidate the role of A1AT in the pathophysiology of COVID-19.
- To explore A1AT as a potential therapeutic target for COVID-19.
Main Methods:
- Literature review focusing on the molecular mechanisms of A1AT.
- Analysis of A1AT's interactions with SARS-CoV-2 entry and replication factors.
- Examination of A1AT's influence on inflammatory pathways relevant to COVID-19.
Main Results:
- A1AT inhibits SARS-CoV-2 infection by blocking TMPRSS2 and ADAM17.
- A1AT modulates inflammatory responses by inhibiting IL-8, TNF-α, and neutrophil elastase.
- A1AT's interaction with ACE2 shedding and renin-angiotensin system balance is highlighted.
- Clinical data suggests A1AT levels correlate with COVID-19 outcomes, potentially linking to air pollution and diabetes.
Conclusions:
- A1AT plays a significant role in mitigating COVID-19 pathophysiology through multiple mechanisms.
- A1AT's inhibitory effects on viral entry and inflammation present therapeutic potential.
- Further investigation into A1AT-based therapies for COVID-19 is warranted.
Related Concept Videos
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation

